Your browser doesn't support javascript.
loading
A novel D-amino acid peptide with therapeutic potential (ISAD1) inhibits aggregation of neurotoxic disease-relevant mutant Tau and prevents Tau toxicity in vitro.
Aillaud, Isabelle; Kaniyappan, Senthilvelrajan; Chandupatla, Ram Reddy; Ramirez, Lisa Marie; Alkhashrom, Sewar; Eichler, Jutta; Horn, Anselm H C; Zweckstetter, Markus; Mandelkow, Eckhard; Sticht, Heinrich; Funke, Susanne Aileen.
Afiliação
  • Aillaud I; Institute of Bioanalysis, Coburg University of Applied Sciences, Coburg, Germany.
  • Kaniyappan S; German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
  • Chandupatla RR; Department of Neurodegenerative Diseases and Geriatric Psychiatry, University of Bonn, Bonn, Germany.
  • Ramirez LM; German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany.
  • Alkhashrom S; Forschungsgruppe Translationale Strukturbiologie, Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE), Göttingen, Germany.
  • Eichler J; Institut für Chemie und Pharmazie, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
  • Horn AHC; Institut für Chemie und Pharmazie, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
  • Zweckstetter M; Bioinformatik, Institut für Biochemie, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
  • Mandelkow E; Institut für Medizinische Genetik, Universität Zürich, Zürich, Switzerland.
  • Sticht H; Forschungsgruppe Translationale Strukturbiologie, Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE), Göttingen, Germany.
  • Funke SA; Abteilung für NMR-basierte Strukturbiologie, Max-Planck-Institut für Biophysikalische Chemie, Göttingen, Germany.
Alzheimers Res Ther ; 14(1): 15, 2022 01 21.
Article em En | MEDLINE | ID: mdl-35063014
ABSTRACT

BACKGROUND:

Alzheimer's disease (AD), the most common form of dementia, is a progressive neurodegenerative disorder that mainly affects older adults. One of the pathological hallmarks of AD is abnormally aggregated Tau protein that forms fibrillar deposits in the brain. In AD, Tau pathology correlates strongly with clinical symptoms, cognitive dysfunction, and neuronal death.

METHODS:

We aimed to develop novel therapeutic D-amino acid peptides as Tau fibrillization inhibitors. It has been previously demonstrated that D-amino acid peptides are protease stable and less immunogenic than L-peptides, and these characteristics may render them suitable for in vivo applications. Using a phage display procedure against wild type full-length Tau (TauFL), we selected a novel Tau binding L-peptide and synthesized its D-amino acid version ISAD1 and its retro inversed form, ISAD1rev, respectively.

RESULTS:

While ISAD1rev inhibited Tau aggregation only moderately, ISAD1 bound to Tau in the aggregation-prone PHF6 region and inhibited fibrillization of TauFL, disease-associated mutant full-length Tau (TauFLΔK, TauFL-A152T, TauFL-P301L), and pro-aggregant repeat domain Tau mutant (TauRDΔK). ISAD1 and ISAD1rev induced the formation of large high molecular weight TauFL and TauRDΔK oligomers that lack proper Thioflavin-positive ß-sheet conformation even at lower concentrations. In silico modeling of ISAD1 Tau interaction at the PHF6 site revealed a binding mode similar to those known for other PHF6 binding peptides. Cell culture experiments demonstrated that ISAD1 and its inverse form are taken up by N2a-TauRDΔK cells efficiently and prevent cytotoxicity of externally added Tau fibrils as well as of internally expressed TauRDΔK.

CONCLUSIONS:

ISAD1 and related peptides may be suitable for therapy development of AD by promoting off-pathway assembly of Tau, thus preventing its toxicity.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Peptídeos / Proteínas tau / Doença de Alzheimer Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Peptídeos / Proteínas tau / Doença de Alzheimer Idioma: En Ano de publicação: 2022 Tipo de documento: Article